Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
46.41
+0.27 (0.57%)
Dec 3, 2024, 12:09 PM EST - Market open
Apogee Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Apogee Therapeutics stock have an average target of 81.17, with a low estimate of 43 and a high estimate of 110. The average target predicts an increase of 74.92% from the current stock price of 46.41.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for APGE stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 5 | 5 |
| Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Reiterates $95 → $110 | Strong Buy | Reiterates | $95 → $110 | +137.04% | Dec 3, 2024 |
| Wedbush | Wedbush | Buy Maintains $87 → $90 | Buy | Maintains | $87 → $90 | +93.94% | Dec 2, 2024 |
| Guggenheim | Guggenheim | Strong Buy Maintains $95 → $110 | Strong Buy | Maintains | $95 → $110 | +137.04% | Nov 27, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $89 | Strong Buy | Initiates | $89 | +91.79% | Nov 25, 2024 |
| Wedbush | Wedbush | Buy Reiterates $87 | Buy | Reiterates | $87 | +87.48% | Oct 25, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.07
from -3.36
EPS Next Year
-4.40
from -3.07
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | n/a | |||
| Avg | n/a | n/a | n/a | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.31 | -2.85 | -4.17 | |||
| Avg | -3.07 | -4.40 | -6.28 | |||
| Low | -3.62 | -7.47 | -11.81 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.